Skip Navigation LinksHome > November 2013 - Volume 119 - Issue 5 > Using Exome Data to Identify Malignant Hyperthermia Suscepti...
Anesthesiology:
doi: 10.1097/ALN.0b013e3182a8a8e7
Perioperative Medicine

Using Exome Data to Identify Malignant Hyperthermia Susceptibility Mutations

Gonsalves, Stephen G. M.S.N.*; Ng, David M.D.; Johnston, Jennifer J. Ph.D.; Teer, Jamie K. Ph.D.§; NISC Comparative Sequencing Program; Stenson, Peter D. Ph.D.#; Cooper, David N. Ph.D.**; Mullikin, James C. Ph.D.††; Biesecker, Leslie G. M.D.‡‡

Supplemental Author Material
Collapse Box

Abstract

Background: Malignant hyperthermia susceptibility (MHS) is a life-threatening, inherited disorder of muscle calcium metabolism, triggered by anesthetics and depolarizing muscle relaxants. An unselected cohort was screened for MHS mutations using exome sequencing. The aim of this study was to pilot a strategy for the RYR1 and CACNA1S genes.
Methods: Exome sequencing was performed on 870 volunteers not ascertained for MHS. Variants in RYR1 and CACNA1S were annotated using an algorithm that filtered results based on mutation type, frequency, and information in mutation databases. Variants were scored on a six-point pathogenicity scale. Medical histories and pedigrees were reviewed for malignant hyperthermia and related disorders.
Results: The authors identified 70 RYR1 and 53 CACNA1S variants among 870 exomes. Sixty-three RYR1 and 41 CACNA1S variants passed the quality and frequency metrics but the authors excluded synonymous variants. In RYR1, the authors identified 65 missense mutations, one nonsense, two that affected splicing, and one non–frameshift indel. In CACNA1S, 48 missense, one frameshift deletion, one splicing, and one non–frameshift indel were identified. RYR1 variants predicted to be pathogenic for MHS were found in three participants without medical or family histories of MHS. Numerous variants, previously described as pathogenic in mutation databases, were reclassified by the authors as being of unknown pathogenicity.
Conclusions: Exome sequencing can identify asymptomatic patients at risk for MHS, although the interpretation of exome variants can be challenging. The use of exome sequencing in unselected cohorts is an important tool to understand the prevalence and penetrance of MHS, a critical challenge for the field.

© 2013 American Society of Anesthesiologists, Inc.

Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.
Login

Article Tools

Share